Senti Biosciences

Yahoo Finance • last year

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver... Full story

Yahoo Finance • last year

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milestones and royalties – SOUTH SAN FRANC... Full story

Yahoo Finance • last year

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies - - Abstracts include new preclinical data demonstrating ongoing progress from collaboratio... Full story

Yahoo Finance • last year

Senti Bio to Participate in Upcoming Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable disea... Full story

Yahoo Finance • last year

Senti Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable disea... Full story

Yahoo Finance • last year

(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson Fistel

SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Pardes Bioscienc... Full story

Yahoo Finance • last year

Edelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Senti Biosciences, Incorporated (NASDAQ: SNTI) Shareholders Who Held Dynamics Special Purpose Corp. (NASDAQ: DYNS) Shares Prior to the Merger

NEWTOWN, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating securities fraud and breach of fiduciary duty claims on behalf of shareholders of Dynamics Special Purpose Corp. (NASDAQ: DYNS), a spec... Full story

Yahoo Finance • 2 years ago

(SPAC) Special Purpose Acquisition Investigation: BBAI, TNGX, SNTI, GMTX, Contact Shareholder Rights Law Firm Johnson Fistel

SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs") and whether invest... Full story

Yahoo Finance • 2 years ago

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

- Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology - - New preclinical data demonstrate ongoing progress from collaborations with... Full story

Yahoo Finance • 2 years ago

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 – – Additional data presented on SENTI-301A and crIL-15 support Senti’s development of gen... Full story

Yahoo Finance • 2 years ago

(SPAC) Special Purpose Acquisition Investigation: BBAI, TNGX, SNTI, BOXD, Contact Shareholder Rights Law Firm Johnson Fistel

SAN DIEGO, March 29, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): BigBear.ai Hold... Full story

Yahoo Finance • 2 years ago

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform,... Full story

Yahoo Finance • 2 years ago

(SPAC) Special Purpose Acquisition Investigation: ADN, TNGX, SNTI, OPFI, Contact Shareholder Rights Law Firm Johnson Fistel

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Advent Technolo... Full story

Yahoo Finance • 2 years ago

Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology... Full story

Yahoo Finance • 2 years ago

Senti Bio to Present at the SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology... Full story

Yahoo Finance • 2 years ago

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors – – SENTI-202 on tr... Full story